Copyright
©The Author(s) 2020.
World J Meta-Anal. Feb 28, 2020; 8(1): 27-40
Published online Feb 28, 2020. doi: 10.13105/wjma.v8.i1.27
Published online Feb 28, 2020. doi: 10.13105/wjma.v8.i1.27
Figure 4 Subgroup analysis of overall survival and disease-free survival [capecitabine plus oxaliplatin (XELOX) vs other chemotherapy groups].
A: The capecitabine plus oxaliplatin (XELOX) group had longer overall survival compared with other chemotherapy groups; B: The XELOX group had longer disease-free survival compared with other chemotherapy groups.
- Citation: Fu HT, Xu YY, Tian JJ, Fu JX, Nie SL, Tang YY, Chen P, Zong L. Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis. World J Meta-Anal 2020; 8(1): 27-40
- URL: https://www.wjgnet.com/2308-3840/full/v8/i1/27.htm
- DOI: https://dx.doi.org/10.13105/wjma.v8.i1.27